HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

SDZ CPI 975

a reversible inhibitor of carnitine palmitoyl transferase I; structure in first source

Also Known As:

SDZ-CPI-975

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Kitahara, M: 1 article (06/2000)
2.	Naitoh, T: 1 article (06/2000)
3.	Tsuruzoe, N: 1 article (06/2000)
4.	Yotsumoto, T: 1 article (06/2000)

Related Diseases

1.	Hypertrophy 06/16/2000 - "One-week administration of SDZ CPI 975 caused neither cardiac nor hepatic hypertrophy. " 06/16/2000 - "We investigated the effect of two types of carnitine palmitoyltransferase I inhibitors, ethyl 2-(6-(4-chlorophenoxy)hexyl)oxirane-2-carboxylate (etomoxir) and (R)-3-carboxy-N,N, N-trimethyl-2-¿[hydroxy(tetradecyloxy)phosphinyl]oxy¿-1-propana minium hydroxide (SDZ CPI 975), on cardiac and hepatic hypertrophy in ddY mice. "
2.	Cardiomegaly (Heart Hypertrophy) 01/01/1998 - "SDZ-CPI-975 did not increase glucose utilization by heart muscle, suggesting that CPT I inhibition with SDZ-CPI-975 would not induce cardiac hypertrophy. "

Related Drugs and Biologics

1.	Glucose (Dextrose)
2.	Carnitine O-Palmitoyltransferase (Carnitine Palmitoyltransferase II)
3.	etomoxir
4.	hydroxide ion
5.	2- cyclohexylidenhydrazo- 4- phenyl- thiazole